BRCAI antikoerper, BRCC1 antikoerper, BROVCA1 antikoerper, IRIS antikoerper, PNCA4 antikoerper, PPP1R53 antikoerper, PSCP antikoerper, RNF53 antikoerper, iris antikoerper, pscp antikoerper, brcai antikoerper, brcc1 antikoerper, rnf53 antikoerper, brca1 antikoerper, BRCA1 antikoerper, LOC100224649 antikoerper, BRCA1, DNA repair associated antikoerper, breast cancer 1 antikoerper, breast cancer 1, early onset antikoerper, breast cancer 1 L homeolog antikoerper, BRCA1 antikoerper, brca1 antikoerper, LOC755086 antikoerper, Brca1 antikoerper, brca1.L antikoerper
Hintergrund
In 1990, a breast cancer susceptibility gene designated BRCA1 was localized to chromosome 17q. Mutations within this gene are believed to account for approximately 45 % of families with high incidence of breast cancer and at least 80 % of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer but, unlike BRCA1, does not confer a substantially elevated risk of ovarian cancer. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a zinc finger domain in its amino terminal region, but is otherwise unrelated to any previously described proteins. Like many other genes involved in familial cancer, BRCA1 appears to encode a tumor suppressor, a protein that acts as a negative regulator of tumor growth.Synonyms: Breast cancer type 1 susceptibility protein, RING finger protein 53